[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"addiction-substance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:addiction-substance":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,69,91,122,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":54,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100619125","neuroimaging-of-adolescent-cannabis-use-treatment-100619125",false,"NCT07340554","Neuroimaging of Adolescent Cannabis Use Treatment","Neuroimaging of Instrumental Learning Networks in Adolescent Cannabis Use Treatment","ACT","Inclusion Criteria:\n\n* 14-17 year old youth\n* Guardian 18 years or older\n* Youth is MRI-eligible: No metal implants, prosthetics, orthodontic devices, transdermal medication patches, piercings and\u002For hair or eyelash extensions that cannot easily be removed, metallic ink tattoos on the neck or face, or claustrophobia, and are not pregnant\n* Youth must endorse having used cannabis at least once per week over the past month OR youth must have been diagnosed with cannabis use disorder within the past three months\n\nExclusion Criteria:\n\n* Youth has a history of Fetal Alcohol Spectrum Disorder, intellectual disorders, pervasive development disorder or autism spectrum disorder, psychotic disorders, history of neurological problems (epilepsy, traumatic brain injury, brain tumor, cerebrovascular disease) by parent\u002Fguardian report\n* Youth or caretaker who is monolingual non-English speaker\n* Youth who is currently experiencing active psychosis symptoms or suicidal\u002Fhomicidal ideation or who has been hospitalized within the past 6 months for psychosis or suicidality\u002Fhomicidality\n* Youth who is currently undergoing contingency management treatment for cannabis use disorder","ALL","14 Years","17 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is testing whether brain activity related to learning can help predict how well teens respond to a treatment program designed to reduce cannabis use. Teens ages 14-17 will complete a brain scan and then take part in 10 weekly virtual sessions where they report cannabis use and complete drug tests at home. Participants can earn prizes for staying cannabis-free.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Cannabis Use","Cannabis Dependence","Cannabis Use Disorder","Cannabis Abuse","Cannabis Intoxication","Cannabis Smoking","Cannabis Withdrawal","Cannabis-Related Disorder","Cannabis Abuse, in Remission","Cannabis Abuse, Episodic Use","Marijuana","Marijuana Abuse","Marijuana Use","Marijuana Smoking","Marijuana Dependence","Marijuana User","Marijuana-Related Disorder","Marijuana Use Disorder","Addiction","Addiction, Substance","Substance Use","Substance Use Disorders","Substance Dependence","Substance Abuse","Substance Related Problem","Substance Abuse Drug Chronic",[55,38,46],"Cannabis","RECRUITING","2026-06-18",{"date":59,"type":60},"2026-06-22","ACTUAL",{"date":62,"type":60},"2026-06-15",{"date":64,"type":22},"2030-05-01",{"name":66,"class":67},"Indiana University","OTHER",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":5},"100408499","efficiency-of-prevention-program-dedicated-to-addictive-behaviors-preventure-of-vulnerable-teenagers-100408499","NCT04599270","Efficiency of Prevention Program Dedicated to Addictive Behaviors (PREVENTURE) of Vulnerable Teenagers","PREVADO","Inclusion Criteria:\n\n* Aged between 14 and 17 years old\n* Patient consulting in one of the participating centres or referred by a school doctor\n* Patient who has had at least one previous experience with alcohol (at least 1 standard unit of alcohol, once in their lifetime)\n* Having access to an internet network and a computer, tablet or telephone\n* Written and informed consent of the parents and the teenager\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Moderate to Severe Adolescent Substance Use Disorders (other than smoking)\n* Decompensated current psychiatric disorders in adolescents\n* Already followed for severe use disorders and\u002For severe psychiatric disorders\n* Nonunderstanding of the french language",{"count":77,"type":22},700,[25],"At the age of 17, in Brittany, 94.9% of adolescents have experimented alcohol consumption 78.1% within a month and 25.5% report repeated episodes of Intensive Punctual Alcohol. Among the potential explanatory factors of this worrying epidemiology, social and cultural factors induce a social valuation of alcohol consumption and drunkenness. There are also individual vulnerability factors, particularly important in adolescence between experimentation and the transition to regular use or even to alcohol use disorders. Despite the extent of the damage, there is currently little reliable data on effective primary prevention strategies for dealing with addictive behavior. Many prevention programs target age range in school settings, to delay or reduce use of psychoactive substances.\n\nA meta-analysis on the impact of this prevention programs in school settings, concluded that most interventions are associated with no or little impact with respect to the goal of reducing psychoactive substances with teenagers.\n\nAmong existing programs, \"PREVENTURE\" has been evaluated in 5 trials with high-risk teenagers identified in schools settings, in different countries (Canada, Europe). The results show a clear and robust effect on reducing alcohol consumption. This program has not been tested outside the school setting and a recent review mention the need to make this program more accessible by targeting vulnerable groups and studying the impact of this program on this population.\n\nThe PREVADO study is a prospective, controlled, randomised, open-label study. After inclusion, the adolescent completes the questionnaire SURPS (Substance Use Risk Profile Scale).\n\nThe SURPS is self-report questionnaire that assesses four well-validated personality risk factors for substance misuse (Impulsivity, Sensation Seeking, Anxiety Sensitivity, and Hopelessness). There is a 23-item to which adolescents are asked to respond using a 4-point Likert scale ranging from \"strongly agree\" to \"strongly disagree\" : Hopelessness (7 items), Anxiety Sensitivity (5 items), Impulsivity (5 items), and Sensation Seeking (6 items).\n\nAdolescents will be randomized into 2 groups (stratification on the 4 predominant risk personality types from the SURPS (Substance Use Risk Profile Scale) and on the recruitment modality) :\n\n* Intervention group : teenagers follow the \"PREVENTURE\" program and routine cares\n* Control group : teenagers follow routine cares",[81,47],"Addiction, Alcohol","2026-06-08",{"date":84,"type":60},"2026-06-10",{"date":86,"type":60},"2021-10-01",{"date":88,"type":22},"2027-10-01",{"name":90,"class":67},"University Hospital, Brest",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":17,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100504925","phase-2-clinical-trial-of-high-dose-lisdexamfetamine-and-contingency-management-in-ma-users-100504925","NCT05854667","Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users","Addition of High Dose Stimulant and Engagement-focused Contingency Management (CM), Alone and in Combination, to Treatment as Usual (TAU) for the Management of Methamphetamine (MA) Use Disorder (ASCME): a Canadian Multi-centre, RCT","Inclusion Criteria:\n\n* Participant must meet all the following criteria:\n\n  1. Between 18 and 55 years of age;\n  2. Diagnosed with a moderate to severe methamphetamine (MA) use disorder as defined by the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) criteria;\n  3. Active MA use at screening measured via self-reported MA use ≥14 days in the past 28 days AND verified by urine drug metabolite testing;\n  4. Interested in reducing\u002Fstopping MA use;\n  5. If female:\n\n     1. Be of non-childbearing potential, defined as (i) postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or (ii) documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or\n     2. Be of childbearing potential, have a negative pregnancy test at screening, and agree to use an acceptable method of birth control throughout the study;\n  6. Willing to be randomized to one of the 4 study arms and followed for the duration of the trial;\n  7. Able to provide informed consent;\n  8. Willing to comply with study procedures;\n  9. Able to communicate in English or French.\n\nExclusion Criteria:\n\n* 1\\. Symptomatic or advanced cardiovascular disease (e.g., advanced arteriosclerosis), moderate hypertension; current hyperthyroidism confirmed via blood test; known hypersensitivity or idiosyncrasy to the sympathomimetic amines or glaucoma or any disabling, severe, OR unstable medical condition that, in the opinion of the study physician, precludes safe participation or the ability to provide fully informed consent; 2. Any severe or unstable co-morbid substance use disorder that, in the opinion of the study physician, precludes safe participation in the study; 3. Participants with Opioid Use Disorder (OUD) who have been on Opioid Agonist Therapy (OAT) for \\\u003C 12 weeks, and not yet at stabilization dose, or at stabilization dose \\\u003C 4 weeks; 4. Current or history of any serious psychiatric disorder (e.g., bipolar disorder, pre-existing psychosis, schizophrenia) that, in the opinion of the study physician, precludes safe participation in the study; 5. History of a severe adverse event, hypersensitivity or known allergic reaction to LDX or other amphetamine drugs OR hypersensitivity to the sympathomimetic amines; 6. Pregnant, nursing, or planning to become pregnant during the study period; 7. Planned extended absence during study period (e.g., pending legal action, surgery, incarceration, inpatient residential program) in the opinion of the study physician that might prevent completion of the study; 8. Use of an investigational drug for stimulant use disorder during the 30 days prior to screening, confirmed via self-report OR pharmacy records; 9. Currently receiving contingency management for the treatment of stimulant use disorder in the 4 weeks prior to screening, confirmed via self-report OR site records; 10. Use of prescribed amphetamine-type medication OR medication for the treatment of stimulant use disorder (e.g., methylphenidate, modafinil, bupropion) in the 4 weeks prior to screening; 11. Current or anticipated need for treatment with any medication that may interact with LDX (e.g., proton pump inhibitors, monoamine oxidase inhibitors \\[MAOIs\\]) used currently or within the past 14 days AND that would preclude study participant at the discretion of the study physician",true,"18 Years","55 Years",{"count":102,"type":22},440,[104],"PHASE2","The goal of this clinical trial is to learn if administering a high dose stimulant with Contingency Management reduces days of use in adults who use methamphetamine better than the usual treatment provided by the clinic.\n\nThe main questions the trial aims to answer are:\n\nIs a high dose stimulant better than a placebo and usual treatment at helping reduce the number of days they use methamphetamine? Is a high dose stimulant with contingency management better than placebo and usual treatment at helping people reduce the number of days they use methamphetamine?\n\nParticipants will be placed randomly into one of four groups:\n\n1. Usual treatment and placebo\n2. Usual treatment, placebo and contingency management\n3. Usual treatment and high dose stimulant\n4. Usual treatment, high dose stimulant and contingency management\n\nParticipation includes the following:\n\n1. Participants will receive medication or placebo weekly for 15 weeks.\n2. Participants will attend the clinic for weekly treatment\n3. Participants will attend the clinic once every 2 weeks for study visits. Each visit will take about an hour to complete. At these visits, participants will be asked to provide a urine sample and complete questionnaires.",[107,108,47,46],"Methamphetamine Abuse","Methamphetamine-dependence",[110,111],"Contingency Management","Treatment as Usual","2026-02-03",{"date":114,"type":60},"2026-02-05",{"date":116,"type":60},"2023-12-05",{"date":118,"type":22},"2028-04",{"name":120,"class":67},"Centre hospitalier de l'Université de Montréal (CHUM)",4,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":99,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":133,"conditions":134,"keywords":138,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":68},"100568002","validation-of-the-french-version-of-the-prediction-of-the-alcohol-withdrawal-severity-scale-pawss-100568002","NCT06675539","Validation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS)","PAWSS-VF","Inclusion Criteria:\n\n* Male or female, aged 18 to 60 years\n* Subjects with DSM-5 criteria for alcohol use disorders (AUD)\n* Subjects hospitalized for scheduled withdrawal or patients developing alcohol withdrawal hospitalized for another reason.\n* Subjects who understand French\n* Subject affiliated to the French social security system\n* Subject having given their written consent to the study\n\nExclusion Criteria:\n\n* Subjects transferred from other hospitalization services for whom a withdrawal syndrome could have already been treated.\n* Subjects scheduled for discharge within 48 hours.\n* Subjects with known uncontrolled epilepsy.\n* Subjects unable to understand the questionnaire.\n* Subjects unable to give consent or not volunteering for the study.\n* Subjects under guardianship or curatorship.","60 Years",{"count":131,"type":22},545,"OBSERVATIONAL","The goal of this observational study is to validate the French version of the PAWSS scale in a population of patients with Alcohol Use Disorders. Prediction of Alcohol Withdrawal Severity Scale (PAWSS) has an excellent psychometric characteristics and predictive value of complicated alcohol withdrawal.\n\nThe main question it aims to answer is:\n\nAre the psychometric properties of the French version of the PAWSS scale comparable to those of the English version in a population of alcohol use disorders subjects?\n\nAUDs participants are included and followed for three days during their hospitalization, They will performed several scales and surveys (DSM-5 AUD criteria, AUDIT, French version of PAWSS and CIWA-AR).",[47,135,136,137],"Alcohol Use Disorder","Alcohol Dependence","Alcohol Withdrawal",[135,139,140,141,142],"Scale","alcohol withdrawal","prediction","withdrawal syndrome","2025-02-24",{"date":145,"type":60},"2025-02-25",{"date":147,"type":60},"2024-11-11",{"date":149,"type":22},"2027-10",{"name":151,"class":67},"Etablissement Public de Santé Barthélemy Durand",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":98,"sex":17,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":68},"100521970","pain-clinic-provides-public-health-safety-100521970","NCT06076512","Pain Clinic Provides Public Health Safety","Pain Clinic Provides Public Health and Safety Services","Inclusion Criteria:\n\n* adult chronic pain patients\n* patients with psychosocial problems\n\nExclusion Criteria:\n\n* pediatric patients\n* patients with severe cognitive dysfunction","20 Years","99 Years",{"count":162,"type":22},1000,"Chronic pain is associated with psychological disorders; which may affect a patient's socioeconomic, legal, domestic, and employment situations. This prospective observational study evaluates the impact of pain management on patients' health, social, economic, and employment status. It explores the impact of pain clinic services on patients' mental health, family health, public health, road safety, addiction situation, public safety, injury rehabilitation and employment situation.",[165,47,166,167,168,169],"Social Functioning","Safety Issues","Road Injury","Patient Compliance","Chronic Pain","2025-01-23",{"date":172,"type":60},"2025-01-27",{"date":174,"type":60},"2018-02-02",{"date":176,"type":22},"2025-12-31",{"name":178,"class":67},"Salem Anaesthesia Pain Clinic"]